Resveratrol therapy improves liver function via estrogen-receptors after hemorrhagic shock in rats.
Animals
Cytokines
/ pharmacology
Estrogen Receptor Antagonists
/ pharmacology
Estrogens
/ pharmacology
Fulvestrant
/ pharmacology
Hemorrhage
Indocyanine Green
/ pharmacology
Liver
Male
Rats
Rats, Sprague-Dawley
Receptors, Estrogen
Resuscitation
Resveratrol
/ pharmacology
Ringer's Solution
/ pharmacology
Shock, Hemorrhagic
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
02
2022
accepted:
20
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Resveratrol may improve organ dysfunction after experimental hemorrhagic or septic shock, and some of these effects appear to be mediated by estrogen receptors. However, the influence of resveratrol on liver function and hepatic microcirculation after hemorrhagic shock is unknown, and a presumed mediation via estrogen receptors has not been investigated in this context. Male Sprague-Dawley rats (200-300g, n = 14/group) underwent hemorrhagic shock for 90 min (MAP 35±5 mmHg) and were resuscitated with shed blood and Ringer's solution. Animals were treated intravenously with vehicle (1% EtOH), resveratrol (0.2 mg/kg), the unselective estrogen receptor antagonist ICI 182,780 (0.05 mg/kg) or resveratrol + ICI 182,780 prior to retransfusion. Sham-operated animals did not undergo hemorrhage but were treated likewise. After 2 hours of reperfusion, liver function was assessed either by plasma disappearance rate of indocyanine green (PDRICG) or evaluation of hepatic perfusion and hepatic integrity by intravital microscopy, serum enzyme as well as cytokine levels. Compared to vehicle controls, administration of resveratrol significantly improved PDRICG, hepatic perfusion index and hepatic integrity after hemorrhagic shock. The co-administration of ICI 182,780 completely abolished the protective effect only with regard to liver function. This study shows that resveratrol may improve liver function and hepatocellular integrity after hemorrhagic shock in rats; estrogen receptors mediate these effects at least partially.
Sections du résumé
BACKGROUND
Resveratrol may improve organ dysfunction after experimental hemorrhagic or septic shock, and some of these effects appear to be mediated by estrogen receptors. However, the influence of resveratrol on liver function and hepatic microcirculation after hemorrhagic shock is unknown, and a presumed mediation via estrogen receptors has not been investigated in this context.
METHODS
Male Sprague-Dawley rats (200-300g, n = 14/group) underwent hemorrhagic shock for 90 min (MAP 35±5 mmHg) and were resuscitated with shed blood and Ringer's solution. Animals were treated intravenously with vehicle (1% EtOH), resveratrol (0.2 mg/kg), the unselective estrogen receptor antagonist ICI 182,780 (0.05 mg/kg) or resveratrol + ICI 182,780 prior to retransfusion. Sham-operated animals did not undergo hemorrhage but were treated likewise. After 2 hours of reperfusion, liver function was assessed either by plasma disappearance rate of indocyanine green (PDRICG) or evaluation of hepatic perfusion and hepatic integrity by intravital microscopy, serum enzyme as well as cytokine levels.
RESULTS
Compared to vehicle controls, administration of resveratrol significantly improved PDRICG, hepatic perfusion index and hepatic integrity after hemorrhagic shock. The co-administration of ICI 182,780 completely abolished the protective effect only with regard to liver function.
CONCLUSIONS
This study shows that resveratrol may improve liver function and hepatocellular integrity after hemorrhagic shock in rats; estrogen receptors mediate these effects at least partially.
Identifiants
pubmed: 36227865
doi: 10.1371/journal.pone.0275632
pii: PONE-D-22-04404
pmc: PMC9560221
doi:
Substances chimiques
Cytokines
0
Estrogen Receptor Antagonists
0
Estrogens
0
Receptors, Estrogen
0
Fulvestrant
22X328QOC4
Ringer's Solution
8026-10-6
Indocyanine Green
IX6J1063HV
Resveratrol
Q369O8926L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0275632Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Shock. 2014 Nov;42(5):440-7
pubmed: 25004063
Nutrients. 2017 Aug 17;9(8):
pubmed: 28817064
Oncotarget. 2017 Jul 4;8(27):43799-43809
pubmed: 28415630
Am J Transl Res. 2017 Mar 15;9(3):823-829
pubmed: 28386315
J Anim Physiol Anim Nutr (Berl). 2012 Feb;96(1):66-74
pubmed: 21244525
Diagnostics (Basel). 2019 Aug 31;9(3):
pubmed: 31480421
Shock. 2008 Sep;30(3):324-8
pubmed: 18277952
Shock. 2013 Aug;40(2):129-35
pubmed: 23698550
J Therm Biol. 2019 May;82:70-75
pubmed: 31128661
J Surg Res. 2009 Jan;151(1):132-7
pubmed: 18486152
Ecotoxicol Environ Saf. 2010 Jul;73(5):1078-83
pubmed: 20089305
Liver Transpl. 2008 Apr;14(4):451-9
pubmed: 18383089
Crit Care Med. 2008 Jan;36(1):24-9
pubmed: 18090374
Ann N Y Acad Sci. 2017 Sep;1403(1):70-81
pubmed: 28845517
J Therm Biol. 2019 Jul;83:8-21
pubmed: 31331528
Toxicol Mech Methods. 2011 Jun;21(5):393-9
pubmed: 21426263
World J Hepatol. 2014 Apr 27;6(4):188-98
pubmed: 24799987
Nat Rev Drug Discov. 2006 Jun;5(6):493-506
pubmed: 16732220
Crit Care Med. 2008 Oct;36(10):2863-70
pubmed: 18766086
Shock. 2011 May;35(5):517-23
pubmed: 21192278
World J Gastroenterol. 2008 Dec 14;14(46):7101-6
pubmed: 19084917
Molecules. 2014 Oct 09;19(10):16102-21
pubmed: 25302702
Crit Care Med. 2005 Mar;33(3):629-37
pubmed: 15753757
Expert Opin Ther Targets. 2015 Jul;19(7):997-1010
pubmed: 26073907
Antioxidants (Basel). 2019 Mar 14;8(3):
pubmed: 30875793
Shock. 2008 Jan;29(1):112-8
pubmed: 17666950
Antioxidants (Basel). 2019 Jul 28;8(8):
pubmed: 31357705
Antioxidants (Basel). 2019 Mar 26;8(3):
pubmed: 30917543
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43
pubmed: 9391166
Nutrients. 2019 Jan 06;11(1):
pubmed: 30621358
Int J Mol Sci. 2018 Nov 05;19(11):
pubmed: 30400630
J Trauma Acute Care Surg. 2014 Dec;77(6):926-33
pubmed: 25248062
Mayo Clin Proc. 2006 Sep;81(9):1232-6
pubmed: 16970220
Antioxidants (Basel). 2019 Jul 10;8(7):
pubmed: 31295839
Cell Metab. 2012 May 2;15(5):675-90
pubmed: 22560220
Crit Care Med. 2010 Apr;38(4):1147-54
pubmed: 20081535
J Hepatol. 2013 May;58(5):904-10
pubmed: 23262250
Cell Death Differ. 2016 Feb;23(2):279-90
pubmed: 26184910
J Trauma Acute Care Surg. 2014 Feb;76(2):409-17
pubmed: 24458046
Liver Transpl. 2010 Sep;16(9):1016-32
pubmed: 20818739